Syndax Pharmaceuticals, Inc. at Citi Biopharma Back to School Summit Transcript
Welcome, everyone. We're here in New York City for day two of Citi's Biopharma Back to School Summit, so sharpen your pencils, take out your notebooks. It's my pleasure to have with me -- oh, I should say, I'm Yigal Nochomovitz, senior biotech analyst here at Citi, and it is my great pleasure to have with me senior management from Syndax Pharmaceuticals. Of course, Michael Metzger, CEO; Nick Botwood, CMO and Head of R&D; and Keith Goldan, Chief Financial Officer.
So welcome all of you. Thank you so much for doing this.
Questions & Answers
Michael, obviously a lot is happening in the space. You have two FDA approvals, obviously. One of the questions we are getting recently is just how things are going with Revuforj given now you have the expanded label. So maybe we could start there, talk about NPM1, what are the forces driving your view that you are taking a leading share of that market? And then we'll go from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
